Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors
Rodrigo Dienstmann, Jordi Rodón, Aleix Prat, et al.
Annals of Oncology (2013) Vol. 25, Iss. 3, pp. 552-563
Open Access | Times Cited: 342

Showing 1-25 of 342 citing articles:

The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing
Teresa Helsten, Sheryl K. Elkin, Elisa Arthur, et al.
Clinical Cancer Research (2015) Vol. 22, Iss. 1, pp. 259-267
Open Access | Times Cited: 688
Advances and challenges in targeting FGFR signalling in cancer
Irina S. Babina, Nicholas C. Turner
Nature reviews. Cancer (2017) Vol. 17, Iss. 5, pp. 318-332
Closed Access | Times Cited: 686
Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update
Robert Roskoski
Pharmacological Research (2019) Vol. 152, pp. 104609-104609
Closed Access | Times Cited: 476
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma
Lipika Goyal, Supriya K. Saha, Leah Y. Liu, et al.
Cancer Discovery (2016) Vol. 7, Iss. 3, pp. 252-263
Open Access | Times Cited: 466
Targeting FGFR Signaling in Cancer
Mehdi Touat, Ecaterina Ileana, Sophie Postel‐Vinay, et al.
Clinical Cancer Research (2015) Vol. 21, Iss. 12, pp. 2684-2694
Closed Access | Times Cited: 452
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
Lucia Nogová, Lecia V. Sequist, José Manuel Pérez García, et al.
Journal of Clinical Oncology (2017) Vol. 35, Iss. 2, pp. 157-165
Open Access | Times Cited: 392
Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan–Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors
Josep Tabernero, Rastislav Bahleda, Rodrigo Dienstmann, et al.
Journal of Clinical Oncology (2015) Vol. 33, Iss. 30, pp. 3401-3408
Closed Access | Times Cited: 360
Upregulated lncRNA-UCA1 contributes to progression of hepatocellular carcinoma through inhibition of miR-216b and activation of FGFR1/ERK signaling pathway
Feng Wang, Hou‐Qun Ying, Bangshun He, et al.
Oncotarget (2015) Vol. 6, Iss. 10, pp. 7899-7917
Open Access | Times Cited: 344
Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer
Woonyoung Choi, Bogdan Czerniak, Andrea Ochoa, et al.
Nature Reviews Urology (2014) Vol. 11, Iss. 7, pp. 400-410
Closed Access | Times Cited: 286
Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor
Timothy Perera, Eleonora Jovcheva, Laurence Mévellec, et al.
Molecular Cancer Therapeutics (2017) Vol. 16, Iss. 6, pp. 1010-1020
Open Access | Times Cited: 282
Squamous Cell Cancers: A Unified Perspective on Biology and Genetics
G. Paolo Dotto, Anil K. Rustgi
Cancer Cell (2016) Vol. 29, Iss. 5, pp. 622-637
Open Access | Times Cited: 280
Refining the treatment of NSCLC according to histological and molecular subtypes
Anish Thomas, Stephen V. Liu, Deepa S. Subramaniam, et al.
Nature Reviews Clinical Oncology (2015) Vol. 12, Iss. 9, pp. 511-526
Closed Access | Times Cited: 272
Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application
Young Kwang Chae, Keerthi Ranganath, Peter S. Hammerman, et al.
Oncotarget (2016) Vol. 8, Iss. 9, pp. 16052-16074
Open Access | Times Cited: 269
Lung Cancer Biomarkers
Pamela Villalobos, Ignacio I. Wistuba
Hematology/Oncology Clinics of North America (2016) Vol. 31, Iss. 1, pp. 13-29
Open Access | Times Cited: 239
Personalized Medicine: Recent Progress in Cancer Therapy
Valentina Gambardella, Noelia Tarazona, Juan Miguel Cejalvo, et al.
Cancers (2020) Vol. 12, Iss. 4, pp. 1009-1009
Open Access | Times Cited: 223
Molecular Pathogenesis and Targeted Therapies for Intrahepatic Cholangiocarcinoma
Agrin Moeini, Daniela Sia, Nabeel Bardeesy, et al.
Clinical Cancer Research (2015) Vol. 22, Iss. 2, pp. 291-300
Closed Access | Times Cited: 219
Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes
K. Martin Kortüm, K. Elias, Nur Hafzan Md Hanafiah, et al.
Blood (2016) Vol. 128, Iss. 9, pp. 1226-1233
Open Access | Times Cited: 219
Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib
Ian M. Silverman, Antoine Hollebecque, Luc Friboulet, et al.
Cancer Discovery (2020) Vol. 11, Iss. 2, pp. 326-339
Open Access | Times Cited: 212
Endocrine Resistance in Hormone Receptor Positive Breast Cancer–From Mechanism to Therapy
Aradhana Rani, Justin Stebbing, Georgios Giamas, et al.
Frontiers in Endocrinology (2019) Vol. 10
Open Access | Times Cited: 189
Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma
Mohamed E. Salem, Alberto Puccini, Joanne Xiu, et al.
The Oncologist (2018) Vol. 23, Iss. 11, pp. 1319-1327
Open Access | Times Cited: 176
Tumor biomarkers for diagnosis, prognosis and targeted therapy
Yue Zhou, Lei Tao, Jiahao Qiu, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 160
Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
Eric Santoni‐Rugiu, Linea Cecilie Melchior, Edyta Maria Urbanska, et al.
Cancers (2019) Vol. 11, Iss. 7, pp. 923-923
Open Access | Times Cited: 149
INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models
Phillip C.C. Liu, Holly K. Koblish, Liangxing Wu, et al.
PLoS ONE (2020) Vol. 15, Iss. 4, pp. e0231877-e0231877
Open Access | Times Cited: 141
FGFR Inhibitors in Oncology: Insight on the Management of Toxicities in Clinical Practice
Anuhya Kommalapati, Sri Harsha Tella, Mitesh J. Borad, et al.
Cancers (2021) Vol. 13, Iss. 12, pp. 2968-2968
Open Access | Times Cited: 118
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study
Shubham Pant, Martin Schüler, Gopa Iyer, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 8, pp. 925-935
Closed Access | Times Cited: 102
Page 1 - Next Page

Scroll to top